ASXL1 mutation is a novel risk factor for bleeding in Philadelphia-negative myeloproliferative neoplasms
Department
Oncology and Hematology
Document Type
Article
Publication Title
Leukemia
First Page
210
Last Page
214
DOI
10.1038/s41375-023-02069-7
Volume
38
Issue
1
Publication Date
1-1-2024
Medical Subject Headings
Humans; Neoplasms; Myeloproliferative Disorders (genetics); Philadelphia Chromosome; Mutation; Repressor Proteins (genetics)
PubMed ID
37919607
Recommended Citation
Awada, H., Bhatta, M., Yu, H., Ji, W., Hou, S., Cronin, T., Ba Aqeel, S., Roy, A. M., Faisal, M. S., Kouides, P., Mascarenhas, J., Griffiths, E. A., & Elshoury, A. (2024). ASXL1 mutation is a novel risk factor for bleeding in Philadelphia-negative myeloproliferative neoplasms. Leukemia, 38 (1), 210-214. https://doi.org/10.1038/s41375-023-02069-7
COinS